AMGEN Oncology is ushering in this novel form of IO therapy with several clinical trials targeting different prostate cancer expressing specific proteins. The potential of these new therapies offers hope for a brighter future for prostate cancer patients with advanced disease. For patients interested in this new therapy today, IO clinical trials are open and available.